Abstract
Chronic obstructive pulmonary disease (COPD) is the respiratory condition with the highest prevalence, with over 10% of individuals over the age of 40 presenting with this disease .(1)
The COVID-19 infection has significantly increased morbidity and mortality among COPD patients, as well as the rate of complications within this pathology.
COVID-19 infection is a systemic inflammatory condition, with primary pulmonary involvement, but also with secondary gastrointestinal, cardiovascular, endocrinological, hepatic, renal, and, not least, neurological effects .(2)
The degree of pulmonary involvement and bacterial superinfection have increased the risk of thromboembolic complications: stroke, atrial fibrillation (FiA), and death.